期刊文献+

高胆固醇血症大鼠血管脂联素抵抗的机制探讨 被引量:3

Mechanisms of vascular adiponectin resistance in hypercholesterolemic rats
下载PDF
导出
摘要 目的:观察高胆固醇血症大鼠血管对脂联素(adiponectin,APN)的反应是否发生改变,并探讨其相关机制。方法:将50只雄性SD大鼠随机分为10组,每组5只,分别以正常及高胆固醇饲料喂养0周、4周、8周、12周及16周。喂养结束后,麻醉采血检测血浆中胆固醇和APN的水平。分离大鼠主动脉,检测血管组织中腺苷酸活化的蛋白激酶(AMPK)的磷酸化(p-AMPK)和APN受体(adipoR1)表达的水平。将其血管组织与重组人APN(rAPN)共孵育,再次观察rAPN对血管组织中p-AMPK的影响。将大鼠血浆与rAPN共孵育4 h,观察孵育后的rAPN对人脐静脉血内皮细胞(HUVEC)p-AMPK的影响。结果:与喂养时间相同的正常饲料喂养组相比,以高脂饲料喂养8周、12周及16周后,血浆胆固醇的含量显著升高(8周:P<0.05;12周及16周:P<0.01)。与喂养时间相同的正常饲料喂养组比较,高脂饲料喂养8周时,血浆APN的水平显著升高(P<0.05),随后呈降低趋势,喂养16周时低于正常值。与喂养时间相同的正常饲料喂养组比较,rAPN激活的AMPK的水平在高脂饲料喂养12周后显著降低,且AdipoR1表达的水平在以高脂饲料喂养16周组中显著降低(P<0.05)。以高胆固醇血症大鼠血浆孵育的rAPN与以正常大鼠血浆孵育的rAPN相比,前者刺激HUVECs中AMPK磷酸化的水平显著降低(P<0.01)。结论:高胆固醇血症大鼠存在血管APN抵抗,早期与高脂血浆中存在某种物质抑制APN的活性有关,晚期还与APN的含量及AdipoR1水平的降低有关。 investigate to receive a AIM: To observe vascular responsiveness to adiponectin in hypercholesterolemic rats and to the mechanisms involved. METHODS: Fifty male Sprague Dawley (SD) rats were randomized regular rat chow diet or a high-fat diet for 0 - 16 weeks, and circulating cholesterol and adiponectin levels were determined. The aortas of rats were isolated and the expression of AMPK phosphoralytion (p-AMPK) and adiponectin receptor (AdipoR1) was detected. Aortas were incubated with recombinant full-length adiponectin (rAPN) and rAPN-induced AMPK phosphorylation was observed, rAPN was incubated with rat plasma for 4 h and then the effect of treated rAPN on AMPK phosphorylation in human umbilical vein endothelial cells was observed. RESULTS: Compared with that in rats fed with regular diet, cholesterol concentration increased after 8 weeks of the high-fat diet. Adiponectin levels in animals fed a high-fat diet significantly increased at 8 weeks and rapidly declined thereafter. The expression of rAPN-induced p-AMPK and AdipoR1 was reduced in rats fed a high-fat diet. Pre-incubation of rAPN with high-fat plasma rather than normal plasma significantly decreased the AMPK activation effect. CONCLUSION: The present study demonstrates that hypercholesterolemia causes vascular adiponectin resistance. Adiponectin modification/inactivation by unidentified factors in hypercholesterolemic plasma is likely responsible for early phase adiponectin resistance. A combination of adiponectin modification/inactivation reduced circulating adiponectin and decreased AdipoR1 expression and is responsible for late phase adiponectin resistance.
出处 《心脏杂志》 CAS 2011年第4期450-454,共5页 Chinese Heart Journal
基金 国家自然科学基金项目资助(30700308)
关键词 脂联素抵抗 高胆固醇血症 血管 大鼠 adiponectin hypercholesterolemia vasculature rat mechanisms
  • 相关文献

参考文献15

  • 1Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin [ J]. Trends Cardiovasc Med, 2006, 16(5) : 141 - 146.
  • 2Li R, Wang WQ, Zhang H, et al. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity[ J]. Am J Physiol Endocrinol Metab, 2007, 293 (6) : E1703 - E1708.
  • 3李榕,王文清,张海锋,徐明,王晓明.gANT对高脂大鼠内皮功能的影响及其分子机制[J].心脏杂志,2010,22(3):318-321. 被引量:1
  • 4Zhou L, Deepa SS, Etzler JC, et al. Adiponectin activates AMPac- tivated protein kinase in muscle cells via APPL1/LKBl-dependent and phospholipase C/Ca^2+/Ca^2+/calmodulin-dependent protein kinase kinasedependent pathways [ J ]. J Biol Chem, 2009, 284 (33) :22426 - 22435.
  • 5Goldstein B J, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function [ J ]. J Clin Endocrinol Metab , 2004, 89 (6) :2563 - 2568.
  • 6Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadi- ponectinemia with coronary artery disease in men [ J ]. Arterioscler Thromb Vasc Biol, 2003, 23(1):85-89.
  • 7Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponeetin, in type 2 diabetic patients[J]. Arterloscler Thromb Vasc Biol, 2000, 20(6) :1595 - 1599.
  • 8Semple RK, Halberg NH, Burling K, et al. Paradoxical elevation of high-molecular weight adiponeetin in acquired extreme insulin re- sistance due to insulin receptor antibodies[J]. Diabetes, 2007, 56 (6) :1712 - 1717.
  • 9Kanety H, Hemi R, Ginsberg S, et al. Total and high molecular weight adiponectin are elevated in patients with Lawn syndrome despite marked obesity [ J ]. Eur J Endocrinol, 2009, 161 (6) :837 - 844.
  • 10Rodriguez A, Catalan V, Beeerril S, et al. Impaired adiponectin- AMPK signalling in insulin-sensitive tissues of hypertensive rats [J]. Life Sci, 2008, 83(15-16) :540-549.

二级参考文献19

  • 1Diamant M, Tushuizen ME. The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD[J]. Curr Diab Rep, 2006, 6(4) :279 -286.
  • 2Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism [ J ]. Trends Endocrinol Metab, 2002, 13(2) :84 -89.
  • 3Chandran M, Phillips SA, Ciaraldi T, et al. Adiponeetin: more than just another fat cell hormone? [ J ]. Diabetes Care, 2003, 26 (8) : 2442 - 2450.
  • 4Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients [ J ]. Arterioscler Thromb Vasc Biol, 2000, 20 (6) : 1595 - 1599.
  • 5Ma H, Zhang HF, Yu L , et al. Vasculoprotective effect of insulin in the ischemic/reperfused canine heart : role of Akt-stimulated NO production [ J ]. Cardiovasc Res, 2006, 69 ( 1 ) :57 - 65.
  • 6Yao D, Vlessidis AG, Gou Y, et al. Chemiluminescence detection of superoxide anion release and superoxide dismutase activity: modulation effect of Pulsatilla chinensis [ J ]. Anal Bioanal Chem, 2004, 379:171-177.
  • 7Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men[J]. JAMA, 2002, 288(21 ):2709-2716.
  • 8Boyd CS, Cadenas E. Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis [ J ]. Biol Chem, 2002, 383 ( 3 - 4 ) : 411 - 423.
  • 9Hsueh WA, Lyon C J, Quinones MJ. Insulin resistance and the endothelium[J]. Am JMed, 2004, 117(2) :109 -117.
  • 10Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients[ J]. J Clin Endocrinol Metab, 2004, 89 (1) :200 -206.

同被引文献3

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部